Wintermin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Wintermin

Property Description
Active ingredient Chlorpromazine
Forms Oral tablets, injectable solution, fine granule
Pharmacological class First-Generation (Typical) Antipsychotic, Neuroleptic
Origin Synthetic compound

Identity and Classification

Wintermin is a brand name for a medication whose active ingredient is Chlorpromazine, a substance derived from the phenothiazine chemical structure. It is formally classified as a Neuroleptic Medication and is recognized as a prototypical first-generation (typical) antipsychotic. The drug is consistently listed on the World Health Organization’s (WHO) Model List of Essential Medicines, underscoring its historical and continued clinical importance for addressing priority health concerns.

Compositional Forms and General Purpose

This medication is a single active ingredient product, typically utilizing a salt form such as Chlorpromazine hydrochloride, and is available in multiple dosage forms, including oral tablets and injectable solutions. Its pharmacological profile places it as a low-potency antipsychotic, meaning its action as a dopaminergic antagonist is accompanied by notable calming and sedative properties.

The core purpose of this drug is to stabilize severe mental and emotional distress, helping to control acute agitation and profoundly disorganized thinking patterns. Furthermore, Chlorpromazine is clinically recognized for its strong antiemetic properties, providing crucial relief in situations involving persistent, severe nausea and vomiting. This dual utility makes it a versatile tool for managing both intense mental disturbances and intractable sickness.

Regulatory References

  1. WHO Essential Medicines List (EML) - Chlorpromazine
  2. NIH MedlinePlus Drug Information: Chlorpromazine
  3. NIH StatPearls: Chlorpromazine

What side effects are possible with Wintermin?

Possible Side Effects and Safety Information

Wintermin (chlorpromazine) is associated with adverse reactions that are classified according to frequency and impact on physiological systems, based on regulatory documentation. These reactions are grouped into categories such as Very Common (ge 1/10), Common (ge 1/100), Uncommon, Rare, and those with a Frequency Not Known.

Key areas of regulatory concern involve the Nervous System and Cardiovascular System.


Adverse Reaction Classifications

Very Common Effects (ge 1/10) include Sedation and Somnolence (drowsiness). Common Effects (ge 1/100) include Extrapyramidal Disorder (a group of movement-related effects), Hyperprolactinaemia, and certain ECG changes.

Serious Adverse Reactions explicitly documented in official labeling include Neuroleptic Malignant Syndrome (NMS), a rare but life-threatening condition, and Tardive Dyskinesia, which involves involuntary movements and is associated with chronic use. Sudden Death has been reported, possibly linked to cardiac effects such as Torsade de pointes.


Contextual and Population Safety Notes

Certain safety patterns are noted based on exposure. Orthostatic Hypotension (a drop in blood pressure upon standing) is most common at the beginning of treatment. Tardive Dyskinesia is associated with the duration and cumulative dose of the medication. The regulatory profile includes a caution regarding an increased risk of death when used in older adults with dementia-related psychosis. General safety restrictions include potential interference with thermoregulation and the risk of photosensitivity.

Overdose and Emergency Response

A Wintermin (Chlorpromazine) overdose is a severe medical emergency requiring immediate attention due to documented risks of life-threatening events. Overdose manifestations primarily affect the Central Nervous System (CNS) and the cardiovascular system.

Documented CNS effects range from extreme drowsiness and confusion to loss of consciousness and coma. Other acute neurological signs include seizures and severe motor disturbances, such as muscle spasms, stiffness, and uncontrollable movements of the body.

The most serious outcomes are cardiovascular. Official regulatory documents list the potential for extreme blood pressure changes (hypotension or hypertension), rapid, irregular heartbeat (tachycardia), and potentially fatal arrhythmias like Torsade de pointes and cardiac arrest.

Immediate emergency medical help must be sought if a seizure, collapse, breathing difficulty, or inability to awaken the person occurs. Treatment for overdose is symptomatic and supportive, as no specific antidote is known. Management includes continuous monitoring of vital signs and a mandatory Electrocardiogram (ECG) to assess heart rhythm stability. The medication is generally contraindicated in comatose patients or when other CNS depressants have been ingested.

Therapeutic Uses of Wintermin

What Wintermin Treats: Main Uses and Benefits

Wintermin is commonly used across conditions characterized by periods of heightened symptoms and episodic disturbances in thought and mood, particularly schizophrenia and the manic phase of bipolar disorder. It helps address symptom clusters that may appear suddenly, such as delusions, hallucinations, and profound disorganization. It is also applied in clinical settings marked by heightened patient distress, including situations involving severe, explosive agitation and combative behavior.

This medication provides supportive therapeutic benefit, helping patients cope more steadily with difficult episodes. It also addresses distinct somatic symptoms, including severe and persistent nausea, vomiting, or chronic hiccups (singultus). This is relevant in situations where short-term symptomatic assistance is needed and helps ease the overall symptom load.

“It is considered relevant for easing distressing manifestations across key domains involving heightened symptom expression.”


Quick Fact: Relief for Intractable Hiccups


Regulatory References

  1. NIH StatPearls overview on Chlorpromazine

Eligibility and Restrictions for Use

Official Eligibility Profile

Wintermin (Chlorpromazine phenolphthalinate) is defined by official regulatory documents as being contraindicated in several specific populations, meaning the medicine must not be used:

  • Patients with known hypersensitivity to phenothiazines or a previous history of a severe reaction, such as jaundice or blood dyscrasias, linked to this drug class.
  • Patients in comatose states or with severe central nervous system depression, especially when large amounts of CNS depressants (e.g., alcohol, narcotics) are present.
  • Patients with bone marrow depression or circulatory collapse.

Restricted or Conditional Use

Use is not approved for treating elderly patients with dementia-related psychosis due to a documented increased risk of death. Use is generally not recommended during pregnancy because safety has not been established, and neonates exposed in the third trimester are at risk for withdrawal symptoms. The medicine should also be avoided in children and adolescents whose signs and symptoms suggest Reye's syndrome.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Wintermin (Chlorpromazine) defines critical interaction patterns, focusing on pharmacodynamic risk, contraindicated combinations, and exposure modification.

Contraindicated and Restricted Combinations

Co-administration with agents known to prolong the QT interval, such as specific anti-arrhythmics (e.g., Quinidine) and certain antidepressants (e.g., Citalopram), is formally contraindicated due to the heightened risk of serious heart rhythm disturbances. The use of Adrenaline (Epinephrine) is prohibited for treating hypotension related to Chlorpromazine administration, as the drug can reverse Adrenaline’s pressor effect, leading to a paradoxical decrease in blood pressure.

Pharmacodynamic and Pharmacokinetic Interactions

Co-administration with other Central Nervous System (CNS) depressants (including alcohol and narcotics) carries an officially documented risk of additive effects, leading to intensified sedation and potential respiratory risk. The concurrent use of Levodopa may result in impaired anti-Parkinson effects, and combining with Lithium has been associated with encephalopathic syndrome.

In terms of exposure, substances like Antacids, tea, and coffee are documented to impair oral absorption, potentially reducing the availability of Chlorpromazine. Furthermore, regulatory documents specify that patients with severe renal or hepatic failure face an increased risk of drug accumulation.

Mechanism of Action

How Wintermin Works: Mechanism of Action

Wintermin acts as a positive allosteric modulator on the Glycine Receptors ( GlyR), primarily targeting subunits in the spinal cord, and exhibits secondary activity on GABA A receptors in the brain. This engagement reinforces the body's natural inhibitory neurotransmission, which establishes the primary cellular condition for the mechanism of action.

The drug's interaction with these receptors initiates a cellular cascade by increasing the frequency and duration of chloride ion ( Cl^-) channel opening on the postsynaptic neuron. This rapid influx of negative charge causes hyperpolarization, which inhibits subsequent action potential generation within the central nervous system.

The resulting generalized inhibition across motor and reflex pathways produces the physiological change of decreased muscle tone and diminished reflex excitability. This central motor regulation contributes to the resulting physiological effects, including central nervous system depression and modulation of muscle resting tension.

Dosage and Administration Information

How to Use Wintermin (Chlorpromazine) — Official Administration Guidelines

This section outlines the use of Wintermin, the brand name for chlorpromazine, according to established procedural information.

Administration Scope

Feature Official Labeled Instruction
Route of Administration Oral (tablet or liquid), Deep Intramuscular (IM), Intravenous (IV), and Rectal (suppository)
Dosing Schedule Initial doses must be low and gradually increased (titrated) until the patient is stabilized, then reduced to the lowest effective maintenance dose
Frequency Pattern Typically 2 to 4 times daily (BID, TID, QID) for oral forms, or every 3 to 8 hours as needed (PRN) for parenteral forms.
Timing in Relation to Meals Oral tablets should be taken with a full glass of water.
Age-Group Rules Doses for elderly patients should generally be one-third to one-half the usual adult dose and increased more gradually. The drug is generally not recommended for children under 6 months.

Procedural and Preparation Instructions

  • Preparation for IV Use: The injectable solution must be diluted with 0.9% Sodium Chloride Injection to a concentration not exceeding 1 mg/mL.
  • IV Infusion Rate: The diluted solution should be administered slowly, typically not exceeding 1 mg/minute in adults.
  • IM Injection: The injection must be given deep into the upper, outer quadrant of the buttock, and injection sites should be rotated for multiple doses.
  • Oral Restrictions: Oral tablets should not be crushed or chewed.
  • Post-Administration: The patient should remain in a recumbent position (lying down) for at least 30 minutes following any parenteral (IM or IV) administration to reduce the risk of hypotension.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Wintermin

Evidence for use in Schizophrenia

The evidence for this condition was studied for many years, primarily through a large number of Randomized Controlled Trials (RCTs). These individual trials were explored and then summarized in large-scale Systematic Reviews and Meta-analyses. The research examined outcomes related to changes in overall global mental state, measures of symptom severity, and how frequently patients experienced a relapse. Findings describe patterns related to measured changes in symptom scores and how often participants needed to stop the study treatment.

Evidence for use in the Manic Phase of Bipolar Disorder

The research for this application was studied for acute symptom control during phases of heightened symptom activity. Studies explored the drug’s use in trials that included other standard interventions or a placebo. The research monitored outcomes related to the control of manic symptom intensity and the overall change in global clinical state. The evidence base for this application is long-established, which contributes to a coarse grading of moderate evidence level for acute control.

Evidence for use in Severe Nausea, Vomiting, and Hiccups

Wintermin was studied for its application in outcomes related to physical discomfort specifically severe and persistent nausea and vomiting. The evidence base for the antiemetic use has consistency across regulatory documentation, contributing to its classification with a high level of evidence. For the rare indication of intractable singultus (hiccups), the research base primarily consists of small studies, Case Reports, and Observational Data.

What Is Still Uncertain About Wintermin's Research Base

The current body of research highlights certain limitations. The evidence quality varies across studies, leading systematic reviewers to apply cautious ratings in key areas like schizophrenia. Limited information is available regarding the long-term changes in daily functioning or quality of life across the populations studied. Therefore, research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Wintermin (FAQ)

Q: Is it normal to feel very sleepy when I first start taking Wintermin?

A: Yes, official product information documents that drowsiness (somnolence) and sedation are classified as very common side effects. This feeling may be most prominent during the initial days of starting therapy.


Q: What is 'parkinsonian syndrome' as a side effect, and does it go away?

A: Wintermin is associated with Extrapyramidal Symptoms (EPS), which include effects like pseudoparkinsonism. This involves movement effects such as tremors and muscle stiffness. While these symptoms are noted in regulatory information, the likelihood of drug-induced Parkinsonism is particularly associated with prolonged use, especially in elderly patients.


Q: Can Wintermin cause weight gain, and how common is this side effect?

A: Yes, regulatory documents list weight gain as a potential side effect of Wintermin. Official information indicates that monitoring of weight may be necessary during treatment.


Q: Does Wintermin make me more sensitive to the sun or heat?

A: Yes, official labeling advises caution because this medication can cause photosensitivity (increased sensitivity to light) and may impair the body's natural thermoregulatory mechanism. This means there is a noted risk when exposed to extreme temperatures, potentially leading to problems with either being too hot or too cold.


Q: I'm feeling very restless, is this a known side effect of Wintermin?

A: Yes, a type of restlessness and inner agitation called akathisia is recognized as a possible side effect of Wintermin. It is categorized as a type of Extrapyramidal Symptom (EPS).


Q: Can Wintermin affect my eyes or vision, such as causing blurred vision?

A: Yes, blurred vision and dry eyes are listed among the possible side effects. Regulatory sources note that the drug's anticholinergic effects lead to a caution regarding its use in patients with glaucoma.


Q: Does Wintermin cause constipation, and what should I do if it's severe?

A: Yes, constipation is documented as a possible gastrointestinal reaction. Official documents note that caution is advised for patients with a history of chronic constipation due to a rare risk of a serious bowel condition called paralytic ileus.


Q: Can Wintermin interact with common over-the-counter (OTC) cold medicines?

A: Regulatory sources advise that the effects of Wintermin can be intensified by other medicines that cause drowsiness because they act as CNS (Central Nervous System) depressants. This includes certain cold or allergy medicines available over-the-counter.


Q: Why is it important to avoid alcohol while taking Wintermin?

A: Official product information explicitly states that Wintermin can add to the effects of alcohol. This may intensify CNS depression, which could potentially lead to serious reactions such as uncontrollable movements, coma, or irregular heartbeats.


Q: Does Wintermin affect the effectiveness of birth control?

A: Official information indicates that some oral contraceptives, specifically those containing ethinyl estradiol, may potentially increase the concentrations of Wintermin in the blood. This may increase the risk of side effects.


Q: Can Wintermin be used in children?

A: Regulatory information indicates that the use of Wintermin is not recommended for children under 6 months of age. For older children, a lower dosage based on body weight may be used, and monitoring for certain side effects like hypothermia and hypotension is generally performed.


Q: Is Wintermin safe to use if I have a heart condition or irregular heartbeat?

A: Official product information advises caution for persons with cardiovascular disease and those with an irregular heartbeat. Wintermin is associated with QT interval prolongation (an ECG change) and a risk of serious heart rhythm disturbances.


Q: Can Wintermin affect my blood sugar levels?

A: Yes, official information indicates that Wintermin may interfere with the body's control of blood glucose (sugar). It is noted that this could potentially reduce the effectiveness of diabetes medications. In patients with or at risk for diabetes, close monitoring of blood sugar levels is generally included as part of standard care.


Q: What is the risk of Wintermin affecting my liver?

A: Official documentation notes that Wintermin is a known cause of acute and chronic cholestatic liver injury, which involves conditions like jaundice. Patients who already have severe hepatic (liver) failure are known to face an increased risk of the drug accumulating in their system.


Q: Why is a sudden change in my body temperature a concerning side effect?

A: Wintermin depresses the body's thermoregulatory mechanism, meaning it interferes with the natural ability to control temperature. Exposure to extreme temperatures may lead to either dangerous hypothermia or hyperthermia. A sudden, severe change in temperature is also recognized as one of the signs of the serious condition, Neuroleptic Malignant Syndrome (NMS).


Q: What are the signs of a serious side effect called Neuroleptic Malignant Syndrome (NMS)?

A: Regulatory sources describe NMS as a rare but serious condition. Signs include a high fever, very stiff (rigid) muscles, confusion, and sweating. Official guidance indicates that the discontinuation of the drug is generally a necessary step if NMS is suspected.


Q: Is Wintermin known to help with hiccups that won't go away?

A: Yes, the drug's official product information includes an indication for the treatment of intractable hiccups (singultus), which are severe hiccups that won't go away.


Q: Does Wintermin have a calming or sedating effect, and how long does it last each day?

A: Wintermin is known to have strong sedative effects. Regulatory-cited information notes that tolerance to this sedative effect may develop rapidly over time.


Q: Is there a generic version of Wintermin available?

A: Yes, the active ingredient in Wintermin is Chlorpromazine, for which the original patent has expired. Official sources confirm that generic formulations are widely available and are generally recognized as clinically interchangeable with the original branded product.


Q: Why do some people experience dizziness or feel faint when standing up on Wintermin?

A: This feeling is typically due to Orthostatic Hypotension, a sudden drop in blood pressure that occurs when moving from a sitting or lying position to standing. Official information notes that this may be a prominent side effect, especially in acute administration.


Q: Does Wintermin affect sexual function or libido?

A: Yes, regulatory documents list a change in libido (sex drive) and impotence as possible side effects associated with this medication.


Q: Is it true that Wintermin can cause a rare side effect of a blue-grey skin tint?

A: Case reports and clinical history cited in official sources indicate that chlorpromazine is known to induce hyperpigmentation (skin darkening) in rare cases, particularly with chronic use in sun-exposed areas. This change has been described as a blue-grey skin tint.


Q: Can Wintermin cause problems with urination or bladder control?

A: Yes, due to its anticholinergic properties, the medication is known to cause problems with difficulty urinating (urinary retention). Conversely, urinary incontinence (loss of bladder control) is also listed as a possible side effect.


Q: Can Wintermin cause changes in menstrual periods or breast discharge?

A: Official information notes that Wintermin can cause Hyperprolactinaemia (increased levels of the hormone prolactin). High prolactin levels can result in effects such as galactorrhea (breast discharge) and changes to menstrual periods.


Q: Is it possible to develop a tolerance to the sedative effects of Wintermin?

A: Yes, regulatory-cited clinical data indicates that Wintermin has strong sedative properties, and tolerance to this effect may develop rapidly in some individuals.


Q: Will taking Wintermin affect my ability to operate machinery or drive?

A: Official patient information explicitly states that this medication may impair the mental and/or physical abilities required for potentially hazardous tasks, such as driving a car or operating heavy machinery. The official guidance is that caution is generally necessary.


Q: What if I forget to take a dose of Wintermin?

A: Regulatory guidance generally indicates that if a dose is missed, individuals should continue with the next scheduled dose. It is advised that you do not take a double dose to make up for the missed one, as this increases the risk of side effects.


Q: Is it normal to have a stuffy nose when starting Wintermin?

A: Yes, official product documents list nasal congestion (stuffy nose) as one of the possible side effects associated with taking Wintermin.


Q: Why are people with a history of glaucoma cautioned about using Wintermin?

A: The drug is cautioned for use in patients with glaucoma because it has an anticholinergic effect which can cause mydriasis (pupil dilation). This dilation can potentially increase pressure inside the eye.


Q: Can Wintermin affect my concentration or memory?

A: Official information points out that this medication may cause impairment of mental abilities. This can translate to effects on concentration, awareness, and memory.


How should Wintermin be stored and disposed of?

How to Store and Dispose of Wintermin

Wintermin must be stored in the manner specified by official labeling to maintain its quality and strength. Both tablets and the injectable solution require storage at Controlled Room Temperature (20 C to 25 C), and must be strictly protected from light and moisture. Tablets should be kept in a tightly closed, light-resistant container. The injectable solution must be specifically protected from freezing and should not be refrigerated. Users must keep the medication out of the sight and reach of children.

For disposal of unused or expired product, the official guidance is to utilize a drug take-back program. If a program is unavailable, mix the medicine with an unappealing substance and place it in a sealed container before throwing it into household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Wintermin found in:

A-Z Index: